Cargando…
MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines
SIMPLE SUMMARY: Since 2005, temozolomide (TMZ) has been used as a standard first-line treatment for glioblastoma (GBM, grade IV glioma), and despite many studies and efforts no better alternatives have emerged. Tumor recurrences and TMZ resistance are common and the prognosis is very poor with a med...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772739/ https://www.ncbi.nlm.nih.gov/pubmed/35053068 http://dx.doi.org/10.3390/biology11010070 |